Black Diamond Therapeutics to Present Phase 2 Trial Results on December 3
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 02 2025
0mins
Should l Buy BDTX?
Source: Globenewswire
- Clinical Trial Update: Black Diamond Therapeutics will host a webcast on December 3, 2025, at 8:00 AM ET to present results from its Phase 2 clinical trial of silevertinib, targeting oncogenic mutations in cancer patients.
- Therapeutic Innovation: The company's MasterKey therapies focus on addressing a broad spectrum of genetically defined tumors, aiming to overcome resistance and minimize wild-type mediated toxicities, with potential brain penetrance for treating central nervous system diseases.
- Market Positioning: Silevertinib, a fourth-generation EGFR inhibitor developed by Black Diamond, specifically targets EGFR-mutant non-small cell lung cancer and glioblastoma, showcasing significant potential in tumor treatment applications.
- Investor Relations: The company encourages investors to visit the Investors section of its website for the latest financial and material information, ensuring transparency and timely dissemination of information.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BDTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BDTX
Wall Street analysts forecast BDTX stock price to rise
5 Analyst Rating
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 2.030
Low
8.00
Averages
9.00
High
10.00
Current: 2.030
Low
8.00
Averages
9.00
High
10.00
About BDTX
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. It is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Black Diamond Therapeutics Q4 2025 Financial Analysis
- Earnings Performance: Black Diamond Therapeutics reported a Q4 GAAP EPS of -$0.27, missing expectations by $0.09, indicating challenges in profitability.
- Cash Position: As of the end of 2025, the company had approximately $128.7 million in cash, cash equivalents, and investments, a significant increase from $98.6 million as of December 31, 2024, reflecting improved financial management.
- Operating Cash Flow: The company generated $29.6 million in operating cash flow for 2025, a stark contrast to the net cash used in operations of $62.3 million in 2024, showcasing substantial operational efficiency improvements that may support future investments.
- Financial Guidance: Black Diamond believes its cash reserves are sufficient to fund anticipated operating expenses and capital expenditures into the second half of 2028, demonstrating confidence in its future financial stability.
See More
Growth Prospects for the EGFR-NSCLC Market Analyzed
- Market Size Forecast: The EGFR-NSCLC market is projected to reach $6 billion by 2024, with the U.S. accounting for approximately 56% of the total market, indicating strong demand for new therapies and significant economic potential in this region.
- Rising Patient Numbers: In 2024, nearly 117,000 new cases of EGFR-NSCLC are expected, and as testing rates increase, more patients with EGFR mutations are identified, driving the demand for targeted therapies and signaling ongoing market expansion.
- Active Drug Development: Several new drugs, including Zipalertinib and Firmonertinib, are in clinical trials and are anticipated to introduce new treatment options, which not only diversify the therapeutic landscape but also have the potential to redefine existing treatment standards and improve patient survival rates.
- Evolving Competitive Landscape: The convergence of TKIs, ADCs, and gene therapies is intensifying competition in the EGFR-NSCLC market, where future winners will depend on efficacy, resistance coverage, and combination therapy potential, driving innovation and growth in the industry.
See More
PayPal Analyst Changes Stance; Check Out Thursday's Top 5 Downgrades
Analyst Downgrades: JP Morgan downgraded Lennar Corporation from Neutral to Underweight, lowering the price target from $118 to $115, while shares closed at $133.13.
EastGroup Properties: Mizuho downgraded EastGroup Properties from Outperform to Neutral, cutting the price target from $180 to $172, with shares closing at $179.24.
Pentair plc: Barclays downgraded Pentair from Overweight to Equal-Weight, slashing the price target from $127 to $115, as shares closed at $106.47.
PayPal Holdings: JP Morgan downgraded PayPal from Overweight to Neutral, reducing the price target from $85 to $70, with shares closing at $61.24.
See More
Black Diamond's Lung Cancer Treatment Demonstrates 60% Response Rate in Phase 2 Results
Phase 2 Trial Results: Black Diamond Therapeutics reported topline data from its Phase 2 trial of silevertinib in non-small cell lung cancer patients, showing a 60% objective response rate and 86% CNS response rate, with no new safety signals observed.
Stock Performance: Following the trial results, BDTX stock experienced a significant decline of 23.77%, trading at $2.62.
Future Plans: The company plans to present updated trial results in 2026 and is also set to initiate a randomized Phase 2 trial for glioblastoma patients in the first half of 2026.
Financial Outlook: Black Diamond has approximately $135.5 million in cash and investments, which it believes will cover operating expenses into the second half of 2028.
See More
Black Diamond Reports 60% ORR for Silevertinib in NSCLC Patients
- Clinical Trial Results: Silevertinib demonstrated a 60% objective response rate (ORR) in 43 frontline NSCLC patients, with an impressive 86% CNS response rate in those with brain metastases, indicating its potential to redefine treatment standards for non-classical EGFR mutations.
- Future Trial Plans: The company plans to initiate a randomized Phase 2 trial for newly diagnosed glioblastoma (GBM) patients in the first half of 2026, aiming to enroll approximately 150 patients, with preliminary data expected in 2028, showcasing a strong commitment to innovative treatment options.
- Financial Position: As of September 30, 2025, the company reported $135.5 million in cash and equivalents, which is expected to fund operations into the second half of 2028, reflecting solid financial health that supports ongoing research and development.
- Exploration of Partnerships: The company is actively seeking partnership opportunities to advance the pivotal development of Silevertinib, particularly in the NSCLC space, indicating a strategic approach to meet market demands and enhance its competitive position.
See More
Black Diamond Therapeutics Reports 60% ORR for Silevertinib in NSCLC Patients
- Clinical Trial Results: Silevertinib demonstrated a 60% objective response rate (ORR) in 43 frontline NSCLC patients, with an impressive 86% CNS response rate in those with brain metastases, indicating its potential as a significant treatment option for various EGFR mutations.
- Future Trial Plans: The company plans to initiate a randomized Phase 2 trial for newly diagnosed glioblastoma patients in the first half of 2026, aiming to enroll approximately 150 patients, with preliminary data expected in 2028, showcasing a strong commitment to new therapeutic strategies.
- Strong Financial Position: As of September 30, 2025, the company reported $135.5 million in cash and equivalents, which is expected to fund operations into the second half of 2028, ensuring continued investment in R&D and clinical trials.
- Exploration of Partnership Opportunities: Black Diamond is actively seeking partnerships to advance the pivotal development of silevertinib, particularly in the NSCLC space, reflecting the company's keen insight into market demands and strategic positioning.
See More
Black Diamond Therapeutics Q4 2025 Financial Analysis
- Earnings Performance: Black Diamond Therapeutics reported a Q4 GAAP EPS of -$0.27, missing expectations by $0.09, indicating challenges in profitability.
- Cash Position: As of the end of 2025, the company had approximately $128.7 million in cash, cash equivalents, and investments, a significant increase from $98.6 million as of December 31, 2024, reflecting improved financial management.
- Operating Cash Flow: The company generated $29.6 million in operating cash flow for 2025, a stark contrast to the net cash used in operations of $62.3 million in 2024, showcasing substantial operational efficiency improvements that may support future investments.
- Financial Guidance: Black Diamond believes its cash reserves are sufficient to fund anticipated operating expenses and capital expenditures into the second half of 2028, demonstrating confidence in its future financial stability.
See More
Growth Prospects for the EGFR-NSCLC Market Analyzed
- Market Size Forecast: The EGFR-NSCLC market is projected to reach $6 billion by 2024, with the U.S. accounting for approximately 56% of the total market, indicating strong demand for new therapies and significant economic potential in this region.
- Rising Patient Numbers: In 2024, nearly 117,000 new cases of EGFR-NSCLC are expected, and as testing rates increase, more patients with EGFR mutations are identified, driving the demand for targeted therapies and signaling ongoing market expansion.
- Active Drug Development: Several new drugs, including Zipalertinib and Firmonertinib, are in clinical trials and are anticipated to introduce new treatment options, which not only diversify the therapeutic landscape but also have the potential to redefine existing treatment standards and improve patient survival rates.
- Evolving Competitive Landscape: The convergence of TKIs, ADCs, and gene therapies is intensifying competition in the EGFR-NSCLC market, where future winners will depend on efficacy, resistance coverage, and combination therapy potential, driving innovation and growth in the industry.
See More
PayPal Analyst Changes Stance; Check Out Thursday's Top 5 Downgrades
Analyst Downgrades: JP Morgan downgraded Lennar Corporation from Neutral to Underweight, lowering the price target from $118 to $115, while shares closed at $133.13.
EastGroup Properties: Mizuho downgraded EastGroup Properties from Outperform to Neutral, cutting the price target from $180 to $172, with shares closing at $179.24.
Pentair plc: Barclays downgraded Pentair from Overweight to Equal-Weight, slashing the price target from $127 to $115, as shares closed at $106.47.
PayPal Holdings: JP Morgan downgraded PayPal from Overweight to Neutral, reducing the price target from $85 to $70, with shares closing at $61.24.
See More
Black Diamond's Lung Cancer Treatment Demonstrates 60% Response Rate in Phase 2 Results
Phase 2 Trial Results: Black Diamond Therapeutics reported topline data from its Phase 2 trial of silevertinib in non-small cell lung cancer patients, showing a 60% objective response rate and 86% CNS response rate, with no new safety signals observed.
Stock Performance: Following the trial results, BDTX stock experienced a significant decline of 23.77%, trading at $2.62.
Future Plans: The company plans to present updated trial results in 2026 and is also set to initiate a randomized Phase 2 trial for glioblastoma patients in the first half of 2026.
Financial Outlook: Black Diamond has approximately $135.5 million in cash and investments, which it believes will cover operating expenses into the second half of 2028.
See More
Black Diamond Reports 60% ORR for Silevertinib in NSCLC Patients
- Clinical Trial Results: Silevertinib demonstrated a 60% objective response rate (ORR) in 43 frontline NSCLC patients, with an impressive 86% CNS response rate in those with brain metastases, indicating its potential to redefine treatment standards for non-classical EGFR mutations.
- Future Trial Plans: The company plans to initiate a randomized Phase 2 trial for newly diagnosed glioblastoma (GBM) patients in the first half of 2026, aiming to enroll approximately 150 patients, with preliminary data expected in 2028, showcasing a strong commitment to innovative treatment options.
- Financial Position: As of September 30, 2025, the company reported $135.5 million in cash and equivalents, which is expected to fund operations into the second half of 2028, reflecting solid financial health that supports ongoing research and development.
- Exploration of Partnerships: The company is actively seeking partnership opportunities to advance the pivotal development of Silevertinib, particularly in the NSCLC space, indicating a strategic approach to meet market demands and enhance its competitive position.
See More
Black Diamond Therapeutics Reports 60% ORR for Silevertinib in NSCLC Patients
- Clinical Trial Results: Silevertinib demonstrated a 60% objective response rate (ORR) in 43 frontline NSCLC patients, with an impressive 86% CNS response rate in those with brain metastases, indicating its potential as a significant treatment option for various EGFR mutations.
- Future Trial Plans: The company plans to initiate a randomized Phase 2 trial for newly diagnosed glioblastoma patients in the first half of 2026, aiming to enroll approximately 150 patients, with preliminary data expected in 2028, showcasing a strong commitment to new therapeutic strategies.
- Strong Financial Position: As of September 30, 2025, the company reported $135.5 million in cash and equivalents, which is expected to fund operations into the second half of 2028, ensuring continued investment in R&D and clinical trials.
- Exploration of Partnership Opportunities: Black Diamond is actively seeking partnerships to advance the pivotal development of silevertinib, particularly in the NSCLC space, reflecting the company's keen insight into market demands and strategic positioning.
See More
